CA3126706A1 - Analyte sensors and sensing methods for dual detection of glucose and ethanol - Google Patents
Analyte sensors and sensing methods for dual detection of glucose and ethanol Download PDFInfo
- Publication number
- CA3126706A1 CA3126706A1 CA3126706A CA3126706A CA3126706A1 CA 3126706 A1 CA3126706 A1 CA 3126706A1 CA 3126706 A CA3126706 A CA 3126706A CA 3126706 A CA3126706 A CA 3126706A CA 3126706 A1 CA3126706 A1 CA 3126706A1
- Authority
- CA
- Canada
- Prior art keywords
- active area
- ethanol
- glucose
- membrane
- responsive active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title claims abstract description 601
- 239000012491 analyte Substances 0.000 title claims abstract description 278
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims abstract description 230
- 239000008103 glucose Substances 0.000 title claims abstract description 230
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 title claims abstract description 59
- 238000000034 method Methods 0.000 title claims description 29
- 238000001514 detection method Methods 0.000 title description 49
- 230000009977 dual effect Effects 0.000 title description 18
- 102000004190 Enzymes Human genes 0.000 claims abstract description 69
- 108090000790 Enzymes Proteins 0.000 claims abstract description 69
- 238000003780 insertion Methods 0.000 claims abstract description 9
- 230000037431 insertion Effects 0.000 claims abstract description 9
- 239000012528 membrane Substances 0.000 claims description 278
- 229920000642 polymer Polymers 0.000 claims description 161
- 239000012992 electron transfer agent Substances 0.000 claims description 74
- 229940088598 enzyme Drugs 0.000 claims description 68
- 102100033220 Xanthine oxidase Human genes 0.000 claims description 67
- 108010093894 Xanthine oxidase Proteins 0.000 claims description 67
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims description 64
- 108010015776 Glucose oxidase Proteins 0.000 claims description 49
- 239000004366 Glucose oxidase Substances 0.000 claims description 49
- 229940116332 glucose oxidase Drugs 0.000 claims description 49
- 235000019420 glucose oxidase Nutrition 0.000 claims description 49
- 102000016938 Catalase Human genes 0.000 claims description 48
- 108010053835 Catalase Proteins 0.000 claims description 48
- 238000004891 communication Methods 0.000 claims description 30
- 229920002717 polyvinylpyridine Polymers 0.000 claims description 15
- 210000001124 body fluid Anatomy 0.000 claims description 14
- 229910052762 osmium Inorganic materials 0.000 claims description 12
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 claims description 12
- 229920001577 copolymer Polymers 0.000 claims description 10
- 239000010839 body fluid Substances 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 7
- 108010050375 Glucose 1-Dehydrogenase Proteins 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 abstract description 12
- 239000010410 layer Substances 0.000 description 43
- 238000006911 enzymatic reaction Methods 0.000 description 41
- 108010025188 Alcohol oxidase Proteins 0.000 description 38
- 230000033116 oxidation-reduction process Effects 0.000 description 29
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 26
- 239000000758 substrate Substances 0.000 description 26
- 239000002355 dual-layer Substances 0.000 description 25
- 239000000203 mixture Substances 0.000 description 24
- 230000002153 concerted effect Effects 0.000 description 23
- 230000000670 limiting effect Effects 0.000 description 21
- 238000012544 monitoring process Methods 0.000 description 21
- -1 ethanol alcohols Chemical class 0.000 description 16
- 230000004044 response Effects 0.000 description 16
- 238000000151 deposition Methods 0.000 description 15
- 239000002356 single layer Substances 0.000 description 15
- 230000000007 visual effect Effects 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 230000008021 deposition Effects 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 11
- 238000010586 diagram Methods 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 230000000875 corresponding effect Effects 0.000 description 8
- 206010012601 diabetes mellitus Diseases 0.000 description 8
- 238000003618 dip coating Methods 0.000 description 8
- 230000001771 impaired effect Effects 0.000 description 8
- 229910052723 transition metal Chemical class 0.000 description 8
- 150000003624 transition metals Chemical class 0.000 description 8
- CLWRFNUKIFTVHQ-UHFFFAOYSA-N [N].C1=CC=NC=C1 Chemical group [N].C1=CC=NC=C1 CLWRFNUKIFTVHQ-UHFFFAOYSA-N 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 239000008199 coating composition Substances 0.000 description 7
- 238000007254 oxidation reaction Methods 0.000 description 7
- 229920000075 poly(4-vinylpyridine) Polymers 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 230000009471 action Effects 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 230000006735 deficit Effects 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 238000013459 approach Methods 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 239000003431 cross linking reagent Substances 0.000 description 4
- 239000003989 dielectric material Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000004907 flux Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000000446 fuel Substances 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 230000002218 hypoglycaemic effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000004962 physiological condition Effects 0.000 description 4
- 229920002006 poly(N-vinylimidazole) polymer Polymers 0.000 description 4
- 230000027756 respiratory electron transport chain Effects 0.000 description 4
- AOBIOSPNXBMOAT-UHFFFAOYSA-N 2-[2-(oxiran-2-ylmethoxy)ethoxymethyl]oxirane Chemical compound C1OC1COCCOCC1CO1 AOBIOSPNXBMOAT-UHFFFAOYSA-N 0.000 description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
- 208000013016 Hypoglycemia Diseases 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 3
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 238000011088 calibration curve Methods 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 229910001882 dioxygen Inorganic materials 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 238000000835 electrochemical detection Methods 0.000 description 3
- 238000003487 electrochemical reaction Methods 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 239000004971 Cross linker Substances 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 230000014101 glucose homeostasis Effects 0.000 description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 239000012925 reference material Substances 0.000 description 2
- 238000007650 screen-printing Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000001755 vocal effect Effects 0.000 description 2
- PJKPEFPGGBAAJE-UHFFFAOYSA-N 1-hydroxy-3,7-dihydropurine-2,6-dione Chemical compound O=C1N(O)C(=O)NC2=C1NC=N2 PJKPEFPGGBAAJE-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical compound N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- GELXFVQAWNTGPQ-UHFFFAOYSA-N [N].C1=CNC=N1 Chemical group [N].C1=CNC=N1 GELXFVQAWNTGPQ-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000981 bystander Effects 0.000 description 1
- 229940075397 calomel Drugs 0.000 description 1
- 239000003990 capacitor Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 229910021393 carbon nanotube Inorganic materials 0.000 description 1
- 239000002041 carbon nanotube Substances 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 229940105657 catalase Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 238000003869 coulometry Methods 0.000 description 1
- MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- ZOMNIUBKTOKEHS-UHFFFAOYSA-L dimercury dichloride Chemical compound Cl[Hg][Hg]Cl ZOMNIUBKTOKEHS-UHFFFAOYSA-L 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- YMFBFFPJRABBPE-BTVCFUMJSA-N ethanol;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound CCO.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O YMFBFFPJRABBPE-BTVCFUMJSA-N 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000019256 formaldehyde Nutrition 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 235000012209 glucono delta-lactone Nutrition 0.000 description 1
- 229960003681 gluconolactone Drugs 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 229910021389 graphene Inorganic materials 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007641 inkjet printing Methods 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- UETZVSHORCDDTH-UHFFFAOYSA-N iron(2+);hexacyanide Chemical compound [Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] UETZVSHORCDDTH-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 208000013433 lightheadedness Diseases 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000002082 metal nanoparticle Substances 0.000 description 1
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002907 osmium Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920005597 polymer membrane Polymers 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007761 roller coating Methods 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/1468—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means
- A61B5/1486—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means using enzyme electrodes, e.g. with immobilised oxidase
- A61B5/14865—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means using enzyme electrodes, e.g. with immobilised oxidase invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/1468—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means
- A61B5/1473—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/1468—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means
- A61B5/1486—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means using enzyme electrodes, e.g. with immobilised oxidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/16—Devices for psychotechnics; Testing reaction times ; Devices for evaluating the psychological state
- A61B5/18—Devices for psychotechnics; Testing reaction times ; Devices for evaluating the psychological state for vehicle drivers or machine operators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4845—Toxicology, e.g. by detection of alcohol, drug or toxic products
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B60—VEHICLES IN GENERAL
- B60K—ARRANGEMENT OR MOUNTING OF PROPULSION UNITS OR OF TRANSMISSIONS IN VEHICLES; ARRANGEMENT OR MOUNTING OF PLURAL DIVERSE PRIME-MOVERS IN VEHICLES; AUXILIARY DRIVES FOR VEHICLES; INSTRUMENTATION OR DASHBOARDS FOR VEHICLES; ARRANGEMENTS IN CONNECTION WITH COOLING, AIR INTAKE, GAS EXHAUST OR FUEL SUPPLY OF PROPULSION UNITS IN VEHICLES
- B60K28/00—Safety devices for propulsion-unit control, specially adapted for, or arranged in, vehicles, e.g. preventing fuel supply or ignition in the event of potentially dangerous conditions
- B60K28/02—Safety devices for propulsion-unit control, specially adapted for, or arranged in, vehicles, e.g. preventing fuel supply or ignition in the event of potentially dangerous conditions responsive to conditions relating to the driver
- B60K28/06—Safety devices for propulsion-unit control, specially adapted for, or arranged in, vehicles, e.g. preventing fuel supply or ignition in the event of potentially dangerous conditions responsive to conditions relating to the driver responsive to incapacity of driver
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B60—VEHICLES IN GENERAL
- B60K—ARRANGEMENT OR MOUNTING OF PROPULSION UNITS OR OF TRANSMISSIONS IN VEHICLES; ARRANGEMENT OR MOUNTING OF PLURAL DIVERSE PRIME-MOVERS IN VEHICLES; AUXILIARY DRIVES FOR VEHICLES; INSTRUMENTATION OR DASHBOARDS FOR VEHICLES; ARRANGEMENTS IN CONNECTION WITH COOLING, AIR INTAKE, GAS EXHAUST OR FUEL SUPPLY OF PROPULSION UNITS IN VEHICLES
- B60K28/00—Safety devices for propulsion-unit control, specially adapted for, or arranged in, vehicles, e.g. preventing fuel supply or ignition in the event of potentially dangerous conditions
- B60K28/02—Safety devices for propulsion-unit control, specially adapted for, or arranged in, vehicles, e.g. preventing fuel supply or ignition in the event of potentially dangerous conditions responsive to conditions relating to the driver
- B60K28/06—Safety devices for propulsion-unit control, specially adapted for, or arranged in, vehicles, e.g. preventing fuel supply or ignition in the event of potentially dangerous conditions responsive to conditions relating to the driver responsive to incapacity of driver
- B60K28/063—Safety devices for propulsion-unit control, specially adapted for, or arranged in, vehicles, e.g. preventing fuel supply or ignition in the event of potentially dangerous conditions responsive to conditions relating to the driver responsive to incapacity of driver preventing starting of vehicles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/001—Enzyme electrodes
- C12Q1/005—Enzyme electrodes involving specific analytes or enzymes
- C12Q1/006—Enzyme electrodes involving specific analytes or enzymes for glucose
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
- C12Q1/30—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving catalase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
- C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/98—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving alcohol, e.g. ethanol in breath
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B60—VEHICLES IN GENERAL
- B60K—ARRANGEMENT OR MOUNTING OF PROPULSION UNITS OR OF TRANSMISSIONS IN VEHICLES; ARRANGEMENT OR MOUNTING OF PLURAL DIVERSE PRIME-MOVERS IN VEHICLES; AUXILIARY DRIVES FOR VEHICLES; INSTRUMENTATION OR DASHBOARDS FOR VEHICLES; ARRANGEMENTS IN CONNECTION WITH COOLING, AIR INTAKE, GAS EXHAUST OR FUEL SUPPLY OF PROPULSION UNITS IN VEHICLES
- B60K28/00—Safety devices for propulsion-unit control, specially adapted for, or arranged in, vehicles, e.g. preventing fuel supply or ignition in the event of potentially dangerous conditions
- B60K28/02—Safety devices for propulsion-unit control, specially adapted for, or arranged in, vehicles, e.g. preventing fuel supply or ignition in the event of potentially dangerous conditions responsive to conditions relating to the driver
- B60K28/06—Safety devices for propulsion-unit control, specially adapted for, or arranged in, vehicles, e.g. preventing fuel supply or ignition in the event of potentially dangerous conditions responsive to conditions relating to the driver responsive to incapacity of driver
- B60K28/066—Safety devices for propulsion-unit control, specially adapted for, or arranged in, vehicles, e.g. preventing fuel supply or ignition in the event of potentially dangerous conditions responsive to conditions relating to the driver responsive to incapacity of driver actuating a signalling device
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B60—VEHICLES IN GENERAL
- B60W—CONJOINT CONTROL OF VEHICLE SUB-UNITS OF DIFFERENT TYPE OR DIFFERENT FUNCTION; CONTROL SYSTEMS SPECIALLY ADAPTED FOR HYBRID VEHICLES; ROAD VEHICLE DRIVE CONTROL SYSTEMS FOR PURPOSES NOT RELATED TO THE CONTROL OF A PARTICULAR SUB-UNIT
- B60W40/00—Estimation or calculation of non-directly measurable driving parameters for road vehicle drive control systems not related to the control of a particular sub unit, e.g. by using mathematical models
- B60W40/08—Estimation or calculation of non-directly measurable driving parameters for road vehicle drive control systems not related to the control of a particular sub unit, e.g. by using mathematical models related to drivers or passengers
- B60W2040/0818—Inactivity or incapacity of driver
- B60W2040/0836—Inactivity or incapacity of driver due to alcohol
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B60—VEHICLES IN GENERAL
- B60W—CONJOINT CONTROL OF VEHICLE SUB-UNITS OF DIFFERENT TYPE OR DIFFERENT FUNCTION; CONTROL SYSTEMS SPECIALLY ADAPTED FOR HYBRID VEHICLES; ROAD VEHICLE DRIVE CONTROL SYSTEMS FOR PURPOSES NOT RELATED TO THE CONTROL OF A PARTICULAR SUB-UNIT
- B60W2540/00—Input parameters relating to occupants
- B60W2540/24—Drug level, e.g. alcohol
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Public Health (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Optics & Photonics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Mechanical Engineering (AREA)
- Transportation (AREA)
- Combustion & Propulsion (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- General Physics & Mathematics (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962797566P | 2019-01-28 | 2019-01-28 | |
| US62/797,566 | 2019-01-28 | ||
| US201962884841P | 2019-08-09 | 2019-08-09 | |
| US62/884,841 | 2019-08-09 | ||
| PCT/US2020/015400 WO2020159981A1 (en) | 2019-01-28 | 2020-01-28 | Analyte sensors and sensing methods for dual detection of glucose and ethanol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3126706A1 true CA3126706A1 (en) | 2020-08-06 |
Family
ID=69724151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3126706A Pending CA3126706A1 (en) | 2019-01-28 | 2020-01-28 | Analyte sensors and sensing methods for dual detection of glucose and ethanol |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12220235B2 (enExample) |
| EP (2) | EP4552565A1 (enExample) |
| JP (3) | JP7196320B2 (enExample) |
| CN (2) | CN113453620B (enExample) |
| AU (3) | AU2020216330B2 (enExample) |
| CA (1) | CA3126706A1 (enExample) |
| ES (1) | ES2999412T3 (enExample) |
| LT (1) | LT3917393T (enExample) |
| WO (1) | WO2020159981A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3423591B1 (en) | 2016-03-04 | 2023-11-01 | Abbott Diabetes Care Inc. | Nad(p)-dependent responsive enzymes, electrodes and sensors, and methods for making and using the same |
| WO2020159981A1 (en) * | 2019-01-28 | 2020-08-06 | Abbott Diabetes Care Inc. | Analyte sensors and sensing methods for dual detection of glucose and ethanol |
| FI3917394T3 (fi) | 2019-01-28 | 2024-11-12 | Abbott Diabetes Care Inc | Analyyttiantureita, joissa käytetään useita entsyymejä |
| AU2020419193B2 (en) | 2020-01-03 | 2024-07-04 | Abbott Diabetes Care Inc. | Sensor array systems and methods for detecting multiple analytes |
| WO2021163378A1 (en) * | 2020-02-11 | 2021-08-19 | Life Patch International | Devices, methods and systems related to wearable patch having blood alcohol content detector |
| CA3182587A1 (en) | 2020-07-08 | 2022-01-13 | Stephen OJA | Analyte sensors featuring enhancements for decreasing interferent signal |
| WO2022051889A1 (zh) * | 2020-09-08 | 2022-03-17 | 三诺生物传感股份有限公司 | 提高电化学活性的氧化还原酶及含有该氧化还原酶的生物传感器 |
| WO2022109008A1 (en) * | 2020-11-18 | 2022-05-27 | Cercacor Laboratories, Inc. | Glucose sensors and methods of manufacturing |
| AU2021400588B2 (en) * | 2020-12-15 | 2025-04-10 | Abbott Diabetes Care Inc. | Nad(p) depot for nad(p)-dependent enzyme-based sensors |
| CN116634940A (zh) * | 2020-12-18 | 2023-08-22 | 美国雅培糖尿病护理公司 | 用于分析物检测的系统和方法 |
| CN116897014A (zh) * | 2020-12-23 | 2023-10-17 | 美国雅培糖尿病护理公司 | 连续型钾传感器及其使用方法 |
| WO2022139876A1 (en) * | 2020-12-23 | 2022-06-30 | Abbott Diabetes Care Inc. | Analyte sensors with reduced interferent signal and methods |
| US12097760B2 (en) * | 2021-07-28 | 2024-09-24 | Caterpillar Inc. | Methods and systems for detecting a machine operator |
| AU2024205934A1 (en) | 2022-12-30 | 2025-04-17 | Abbott Diabetes Care Inc. | Drug delivery compositions and methods of controlling drug delivery rates of subcutaneous sensors |
| AU2024211188A1 (en) | 2023-01-25 | 2025-07-17 | Abbott Diabetes Care Inc. | Temperature-insensitive membranes for analyte sensors |
| WO2024243577A1 (en) | 2023-05-24 | 2024-11-28 | Abbott Diabetes Care Inc. | Methods for incorporating therapeutic agents into analyte sensors |
| CN116735885B (zh) * | 2023-05-25 | 2025-02-11 | 深圳硅基传感科技有限公司 | 多分析物监测传感器 |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5264105A (en) | 1989-08-02 | 1993-11-23 | Gregg Brian A | Enzyme electrodes |
| US5792621A (en) * | 1995-06-28 | 1998-08-11 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Fiber-optic chemiluminescent biosensors for monitoring aqueous alcohols and other water quality parameters |
| JP2900876B2 (ja) * | 1996-03-19 | 1999-06-02 | サンケン電気株式会社 | 表示装置の電源装置 |
| US5696314A (en) | 1996-07-12 | 1997-12-09 | Chiron Diagnostics Corporation | Multilayer enzyme electrode membranes and methods of making same |
| EP0921198B1 (en) * | 1997-04-24 | 2006-07-19 | ARKRAY, Inc | Method for enzymatically assaying saccharification protein |
| US6736957B1 (en) | 1997-10-16 | 2004-05-18 | Abbott Laboratories | Biosensor electrode mediators for regeneration of cofactors and process for using |
| US6030827A (en) | 1998-01-23 | 2000-02-29 | I-Stat Corporation | Microfabricated aperture-based sensor |
| US6134461A (en) | 1998-03-04 | 2000-10-17 | E. Heller & Company | Electrochemical analyte |
| US6241863B1 (en) | 1998-04-27 | 2001-06-05 | Harold G. Monbouquette | Amperometric biosensors based on redox enzymes |
| US8268143B2 (en) | 1999-11-15 | 2012-09-18 | Abbott Diabetes Care Inc. | Oxygen-effect free analyte sensor |
| US8444834B2 (en) * | 1999-11-15 | 2013-05-21 | Abbott Diabetes Care Inc. | Redox polymers for use in analyte monitoring |
| EP1230249B1 (en) | 1999-11-15 | 2004-06-02 | Therasense, Inc. | Transition metal complexes with bidentate ligand having an imidazole ring |
| US6560471B1 (en) | 2001-01-02 | 2003-05-06 | Therasense, Inc. | Analyte monitoring device and methods of use |
| US6875613B2 (en) * | 2001-06-12 | 2005-04-05 | Lifescan, Inc. | Biological fluid constituent sampling and measurement devices and methods |
| US7501053B2 (en) | 2002-10-23 | 2009-03-10 | Abbott Laboratories | Biosensor having improved hematocrit and oxygen biases |
| CA2521304A1 (en) * | 2003-04-04 | 2004-10-21 | Lumidigm, Inc. | Multispectral biometric sensor |
| US7460898B2 (en) | 2003-12-05 | 2008-12-02 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
| US9763609B2 (en) * | 2003-07-25 | 2017-09-19 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
| US7761130B2 (en) | 2003-07-25 | 2010-07-20 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
| EP1685258A4 (en) | 2003-10-29 | 2007-08-29 | Agency Science Tech & Res | BIOSENSOR |
| WO2005048834A1 (en) | 2003-11-13 | 2005-06-02 | Medtronic Minimed, Inc. | Long term analyte sensor array |
| EP2256493B1 (en) | 2003-12-05 | 2014-02-26 | DexCom, Inc. | Calibration techniques for a continuous analyte sensor |
| JP4802842B2 (ja) | 2006-04-24 | 2011-10-26 | 株式会社デンソー | 健康管理支援装置及び健康管理システム |
| US7831287B2 (en) * | 2006-10-04 | 2010-11-09 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
| US8808515B2 (en) | 2007-01-31 | 2014-08-19 | Abbott Diabetes Care Inc. | Heterocyclic nitrogen containing polymers coated analyte monitoring device and methods of use |
| WO2008157820A1 (en) | 2007-06-21 | 2008-12-24 | Abbott Diabetes Care, Inc. | Health management devices and methods |
| CA2984510C (en) | 2007-09-24 | 2020-06-09 | Ascensia Diabetes Care Holdings Ag | Multi-region and potential test sensors, methods, and systems |
| CA2715624A1 (en) | 2008-02-20 | 2009-08-27 | Dexcom, Inc. | Continuous medicament sensor system for in vivo use |
| US8620398B2 (en) | 2008-06-02 | 2013-12-31 | Abbott Diabetes Care Inc. | Reference electrodes having an extended lifetime for use in long term amperometric sensors |
| EP2163190A1 (de) * | 2008-09-11 | 2010-03-17 | Roche Diagnostics GmbH | Elektrodensystem für Messung einer Analytkonzentration in-vivo |
| US8608922B2 (en) * | 2008-11-07 | 2013-12-17 | The University Of Connecticut | Biosensor for continuous monitoring of metabolites and proteins and methods of manufacture thereof |
| EP4252639A3 (en) | 2009-02-26 | 2024-01-03 | Abbott Diabetes Care Inc. | Method of calibrating an analyte sensor |
| US20100213057A1 (en) | 2009-02-26 | 2010-08-26 | Benjamin Feldman | Self-Powered Analyte Sensor |
| US8721870B2 (en) * | 2009-03-19 | 2014-05-13 | Edwards Lifesciences Corporation | Membrane system with sufficient buffering capacity |
| EP3001194B1 (en) | 2009-08-31 | 2019-04-17 | Abbott Diabetes Care, Inc. | Medical devices and methods |
| WO2011030093A1 (en) | 2009-09-04 | 2011-03-17 | Lifescan Scotland Limited | Glucose measurement method and system |
| US20120181189A1 (en) | 2009-09-24 | 2012-07-19 | Fresenius Medical Care Holdings, Inc. | Amperometric Creatinine Biosensor With Immobilized Enzyme-Polymer Composition And Systems Using Same, And Methods |
| US8545693B2 (en) | 2009-09-29 | 2013-10-01 | Lifescan Scotland Limited | Analyte measurment method and system |
| US20120283537A1 (en) | 2009-10-30 | 2012-11-08 | Petisce James R | Analyte sensor layers and methods related thereto |
| US9402574B2 (en) | 2010-06-25 | 2016-08-02 | The University Of Connecticut | Sensors for analyte detection and methods of manufacture thereof |
| US20130211219A1 (en) | 2010-08-24 | 2013-08-15 | Micro CHIPS ,Inc. | Implantable Biosensor Device and Methods of Use Thereof |
| US9468402B2 (en) * | 2010-12-01 | 2016-10-18 | Pinnacle Technology, Inc. | Tissue implantable microbiosensor |
| EP4397242A3 (en) | 2010-12-09 | 2024-08-28 | Abbott Diabetes Care Inc. | Analyte sensors with a sensing surface having small sensing spots |
| US8608921B2 (en) | 2011-01-20 | 2013-12-17 | Medtronic Minimed, Inc. | Layered enzyme compositions for use with analyte sensors |
| US20140054171A1 (en) * | 2012-02-21 | 2014-02-27 | Abbott Diabetes Care Inc. | Analyte Sensor Utilizing Oxygen as Oxidant |
| WO2013165318A1 (en) * | 2012-05-03 | 2013-11-07 | National University Of Singapore | A mediator-less electrochemical glucose sensing procedure employing the leach-proof covalent binding of an enzyme(s) to electrodes and products thereof |
| US9788765B2 (en) * | 2012-09-28 | 2017-10-17 | Dexcom, Inc. | Zwitterion surface modifications for continuous sensors |
| US8921061B2 (en) | 2012-11-02 | 2014-12-30 | Roche Diagnostics Operations, Inc. | Reagent materials and associated test elements |
| US9344777B2 (en) | 2012-12-20 | 2016-05-17 | Abbott Diabetes Care Inc. | Wireless communication authentication for medical monitoring device |
| US10426383B2 (en) * | 2013-01-22 | 2019-10-01 | Medtronic Minimed, Inc. | Muting glucose sensor oxygen response and reducing electrode edge growth with pulsed current plating |
| US9487811B2 (en) | 2013-03-15 | 2016-11-08 | Abbott Point Of Care Inc. | Biosensor structures for improved point of care testing and methods of manufacture thereof |
| US9562874B2 (en) | 2013-03-15 | 2017-02-07 | Abbott Point Of Care Inc. | Biosensor with improved interference characteristics |
| US9544313B2 (en) | 2013-12-27 | 2017-01-10 | Abbott Diabetes Care Inc. | Systems, devices, and methods for authentication in an analyte monitoring environment |
| EP3797686B1 (en) * | 2014-10-22 | 2024-12-25 | DexCom, Inc. | User interfaces for continuous glucose monitoring |
| JP6584821B2 (ja) * | 2015-04-30 | 2019-10-02 | 株式会社東芝 | 測定用セル、検出装置および分析装置 |
| US10238346B2 (en) * | 2015-09-25 | 2019-03-26 | Sanmina Corporation | System and method for a biosensor integrated in a vehicle |
| US10228341B2 (en) * | 2015-10-15 | 2019-03-12 | Arkray, Inc. | Biosensor |
| US10324058B2 (en) * | 2016-04-28 | 2019-06-18 | Medtronic Minimed, Inc. | In-situ chemistry stack for continuous glucose sensors |
| WO2018079465A1 (ja) | 2016-10-24 | 2018-05-03 | パナソニックヘルスケアホールディングス株式会社 | 電子メディエータの酸化剤 |
| CA3065339A1 (en) | 2017-06-30 | 2019-01-03 | Abbott Diabetes Care Inc. | Method and apparatus for analyte detection using an electrochemical biosensor |
| DE202018006591U1 (de) | 2017-08-18 | 2021-07-21 | Abbott Diabetes Care, Inc. | Systeme und Vorrichtungen betreffend die individualisierte Kalibrierung und/oder Herstellung von medizinischen Vorrichtungen |
| DE102018209611A1 (de) * | 2018-06-14 | 2019-12-19 | RUHR-UNIVERSITäT BOCHUM | Verfahren zur Entfernung von gelöstem Sauerstoff bei einem elektrochemischen Biosensor, der als Sensorenzym eine Oxidase verwendet |
| US11744492B2 (en) | 2018-08-29 | 2023-09-05 | Medtronic, Inc. | Electrochemical sensor including multiple work electrodes and common reference electrode |
| FI3917396T3 (fi) | 2019-01-28 | 2024-11-29 | Abbott Diabetes Care Inc | Analyyttiantureita, joilla voidaan havaita sekä glukoosia että ketoneita |
| CN119454012A (zh) | 2019-01-28 | 2025-02-18 | 美国雅培糖尿病护理公司 | 检测肌酐的分析物传感器和感测方法 |
| FI3917394T3 (fi) | 2019-01-28 | 2024-11-12 | Abbott Diabetes Care Inc | Analyyttiantureita, joissa käytetään useita entsyymejä |
| WO2020159981A1 (en) * | 2019-01-28 | 2020-08-06 | Abbott Diabetes Care Inc. | Analyte sensors and sensing methods for dual detection of glucose and ethanol |
| WO2020194179A1 (en) | 2019-03-24 | 2020-10-01 | Baldwa Mehul | Biosensor for detection of analytes in a fluid |
-
2020
- 2020-01-28 WO PCT/US2020/015400 patent/WO2020159981A1/en not_active Ceased
- 2020-01-28 AU AU2020216330A patent/AU2020216330B2/en active Active
- 2020-01-28 US US16/774,909 patent/US12220235B2/en active Active
- 2020-01-28 CN CN202080011184.5A patent/CN113453620B/zh active Active
- 2020-01-28 EP EP24200291.3A patent/EP4552565A1/en active Pending
- 2020-01-28 CA CA3126706A patent/CA3126706A1/en active Pending
- 2020-01-28 EP EP20707982.3A patent/EP3917393B1/en active Active
- 2020-01-28 LT LTEPPCT/US2020/015400T patent/LT3917393T/lt unknown
- 2020-01-28 CN CN202410171780.XA patent/CN118105070A/zh active Pending
- 2020-01-28 JP JP2021543440A patent/JP7196320B2/ja active Active
- 2020-01-28 ES ES20707982T patent/ES2999412T3/es active Active
-
2022
- 2022-12-14 JP JP2022199250A patent/JP7524288B2/ja active Active
-
2023
- 2023-07-10 AU AU2023204567A patent/AU2023204567B2/en active Active
-
2024
- 2024-07-17 JP JP2024113856A patent/JP2024137994A/ja active Pending
- 2024-12-27 US US19/003,007 patent/US20250221643A1/en active Pending
-
2025
- 2025-08-28 AU AU2025223845A patent/AU2025223845A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250221643A1 (en) | 2025-07-10 |
| JP2024137994A (ja) | 2024-10-07 |
| LT3917393T (lt) | 2024-12-27 |
| CN113453620A (zh) | 2021-09-28 |
| EP4552565A1 (en) | 2025-05-14 |
| EP3917393A1 (en) | 2021-12-08 |
| JP7196320B2 (ja) | 2022-12-26 |
| WO2020159981A1 (en) | 2020-08-06 |
| JP2023027272A (ja) | 2023-03-01 |
| US20200237277A1 (en) | 2020-07-30 |
| AU2020216330A1 (en) | 2021-08-12 |
| AU2020216330B2 (en) | 2023-04-13 |
| JP2022518923A (ja) | 2022-03-17 |
| CN113453620B (zh) | 2024-03-05 |
| JP7524288B2 (ja) | 2024-07-29 |
| AU2025223845A1 (en) | 2025-09-18 |
| AU2023204567B2 (en) | 2025-06-05 |
| US12220235B2 (en) | 2025-02-11 |
| ES2999412T3 (en) | 2025-02-25 |
| EP3917393B1 (en) | 2024-09-18 |
| AU2023204567A1 (en) | 2023-08-03 |
| CN118105070A (zh) | 2024-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023204567B2 (en) | Analyte sensors and sensing methods for dual detection of glucose and ethanol | |
| AU2022283734B2 (en) | Analyte sensors and sensing methods featuring dual detection of glucose and ketones | |
| AU2023203330B2 (en) | Analyte sensors employing multiple enzymes and methods associated therewith |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210713 |
|
| EEER | Examination request |
Effective date: 20210713 |
|
| EEER | Examination request |
Effective date: 20210713 |
|
| EEER | Examination request |
Effective date: 20210713 |
|
| EEER | Examination request |
Effective date: 20210713 |
|
| EEER | Examination request |
Effective date: 20210713 |
|
| EEER | Examination request |
Effective date: 20210713 |
|
| EEER | Examination request |
Effective date: 20210713 |